Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NDI-034858
NDI-034858
Takeda wagers up to $6B on Nimbus’ TYK2 drug
BioPharma Dive
Tue, 12/13/22 - 10:43 am
Takeda
Nimbus Therapeutics
autoimmune diseases
NDI-034858
Nimbus on cloud 9 as psoriasis data support taking rival to Bristol Myers' Sotyktu into phase 3
Fierce Biotech
Wed, 11/30/22 - 10:38 am
Nimbus Therapeutics
Sotyktu
Bristol Myers Squibb
clinical trials
NDI-034858
Nimbus hopes to best Bristol’s Sotyktu
EP Vantage
Fri, 11/4/22 - 10:15 am
Bristol Myers Squibb
Sotyktu
Nimbus
NDI-034858
psoriasis